Application of chlorogenic acid in prevention of aortic dissection
By adding chlorogenic acid to drugs or foods, intervention on aortic dissection has been solved, the problem of lack of effective prevention of aortic dissection in the prior art has been solved, significantly reducing the incidence and mortality of dissection, and providing new for cardiovascular disease prevention strategies.
Patent Information
- Application Number
- CN202410945614.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-15
- Publication Date
- 2024-11-29
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a lack of effective methods for preventing aortic dissection in the prior art, and the disease is rapidly and incurable, and there are serious cardiovascular problems.
chlorogenic acid is used to intervene in the aortic dissection. By adding chlorogenic acid to drugs or food, the specific dosage is 25mg/kg/day, the mice are subjected to gavage intervention to reduce the incidence of aortic dissection.
The survival rate and aortic health of mice with aortic dissection were significantly improved, and the incidence of dissection was reduced, providing a low-cost prevention strategy for patients with susceptible aortic dissection in clinical practice.
Smart Images

Figure CN119033750A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of aortic dissection prevention, and in particular to application of chlorogenic acid in the prevention of aortic dissection. Background Art
[0002] Chlorogenic acid (CGA) is a phenolic acid produced by the action of caffeic acid and quinic acid. It is the main phenolic compound in honeysuckle and is produced in the plant through the shikimic acid pathway. CGA is an orally active antioxidant ingredient. Its hemihydrate is needle-shaped crystals and is easily soluble in hot water, ethanol, and propanol. CGA has significant anti-inflammatory, antioxidant, anti-cancer, and antibacterial properties. Existing studies have shown that CGA can protect cardiovascular, lower blood pressure, and lower blood lipids.
[0003] CGA has good anti-inflammatory and antioxidant effects. Studies have shown that CGA can inhibit LPS-induced mammary inflammatory cell infiltration; can prevent rheumatoid arthritis and its complications; and alleviate renal damage in rats by inhibiting inflammation and oxidative stress. CGA pretreatment can upregulate antioxidant enzymes and inhibit the expression of related inflammatory factors; at the same time, due to the close connection between inflammation and oxidative stress, CGA activates Nrf2 in PC12 cells by clearing ROS to restore mitochondrial function and induce the expression of antioxidant enzymes.
[0004] CGA also plays an important role in lowering blood sugar and blood lipids. It resists obesity by inhibiting the increase of fat and free fatty acids, while reducing total cholesterol, low-density lipoprotein content, increasing high-density lipoprotein content, and improving dyslipidemia. Studies have shown that CGA can improve endothelial cell function through anti-inflammatory / antioxidant effects and inhibition of angiotensin-converting enzyme. CGA has been widely studied in the treatment of cardiovascular diseases: CGA can inhibit hypochlorous acid-induced endothelial cell oxidative stress, improve in vitro angiogenesis by increasing the levels of NO and heme oxygenase-1, and reduce oxidative stress damage to endothelial cells; in addition, CGA alleviates ox-LDL-induced endothelial oxidative stress and mitochondrial dysfunction by activating SIRT1 and regulating the AMPK / PGC-1 signaling pathway.
[0005] Aortic dissection is a disease that develops rapidly and is dangerous. Once it occurs, it is incurable. It has become a world-class problem in the cardiovascular field. Compared with healthy people, patients with aortic dissection have severe dysfunction of aortic endothelial cells, including barrier function damage and mitochondrial function damage. Inflammation often occurs in patients with aortic dissection. At present, CGA is extremely important both in vascular and cardiac protection, but there is a gap in the role of CGA in aortic dissection, which needs further exploration. Summary of the invention
[0006] In view of the deficiencies in the prior art, the purpose of the present invention is to provide the use of chlorogenic acid in preventing aortic dissection, so as to achieve low-cost and effective clinical prevention for people susceptible to aortic dissection.
[0007] In order to solve the above technical problems, the technical solution provided by the present invention is:
[0008] Application of chlorogenic acid in preventing aortic dissection,
[0009] Chlorogenic acid is used to intervene in aortic dissection and reduce the incidence of aortic dissection.
[0010] Preferably, the application is use in preparing medicine or food for intervening aortic dissection.
[0011] Preferably, the dosage of chlorogenic acid for intervention of mice is 25 mg / kg / day.
[0012] A medicine or food comprising the above-mentioned chlorogenic acid, and its use in preventing aortic dissection.
[0013] The beneficial effects of the present invention are:
[0014] Compared with the positive effects of CGA on cardiovascular diseases found in current studies, the present invention focuses on the effects of CGA on aortic dissection, a more specific disease among cardiovascular diseases that has not been studied in related types. Animal experiments have also verified that CGA plays a significant positive protective role in the progression of aortic dissection. CGA can significantly improve the survival rate of mice with aortic dissection and the health of the aorta, and reduce the incidence of dissection, providing a new strategy for the prevention of aortic dissection in the clinical population susceptible to aortic dissection, which is of great research significance. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] The accompanying drawings are used to provide a further understanding of the present invention and constitute a part of the specification. Together with the embodiments of the present invention, they are used to explain the present invention and do not constitute a limitation of the present invention. In the accompanying drawings:
[0016] Figure 1 Schematic diagram of animal experiments.
[0017] Figure 2 The figure is the survival curve of mice in each experimental group.
[0018] Figure 3 The graph shows the incidence of dissection in mice in each experimental group.
[0019] Figure 4 These are the echocardiograms of mice in each experimental group.
[0020] Figure 5 The maximum diameter of the aorta of mice in each experimental group. DETAILED DESCRIPTION
[0021] The preferred embodiments of the present invention are described below in conjunction with the accompanying drawings. It should be understood that the following embodiments are provided only for the purpose of illustration and are not intended to limit the scope of the present invention. Those skilled in the art may make various modifications and substitutions to the present invention without departing from the purpose and spirit of the present invention.
[0022] The present invention provides the use of chlorogenic acid in preventing aortic dissection, comprising the following steps:
[0023] (1) Animal experiment on CGA intervention in mice with aortic dissection
[0024] Animal experiment: Method for inducing aortic dissection in mice:
[0025]
[0026] BAPN feed: Weigh BAPN powder at a ratio of 0.4% by weight.
[0027] CGA preparation: Weigh the CGA powder and calculate the daily gavage volume (H) based on the gavage volume of 100 μL per mouse per day. 2 O), dissolve the weighed CGA powder in 50 μL DMSO, add appropriate amount of distilled water to dilute after ultrasonic homogenization, and store at -20°C.
[0028] Animal experiment groups: 3-week-old mice were selected, including 14 mice in the Control group; 14 mice in the BAPN+CGA intervention group; and 14 mice in the BAPN-induced dissection group.
[0029] Dissection in mice was induced by mixing BAPN powder into feed to make a feed containing 0.4% BAPN. CGA was administered by gavage at a dose of 100 μL per mouse per day, with the CGA powder dissolved in DMSO and diluted with water at a dose of 25 mg / kg / day according to the mouse body weight, for 30 days.
[0030] (2) Evaluation of pathological indicators in animal experiments
[0031] like Figure 2 As shown in the figure, it is the survival curve of mice in each experimental group. By counting the death time of dissection in different groups of mice, the overall survival curve was drawn and statistically analyzed as of 30 days. The results showed that CGA intervention significantly reduced the mortality rate of mice with aortic dissection model.
[0032] like Figure 3The figure shows the incidence of dissection in each experimental group of mice. The mice were sampled after the echocardiogram experiment, and the number of aortic dilatation in different groups of mice was counted, and the incidence of dissection in different groups of mice was calculated, and then the graph and statistical analysis were performed. In the figure, red represents the number of dissection ruptures that caused death in the model mice, blue represents the number of dissections in the model mice that did not cause death, and black represents the number of model mice that did not have dissections. The results showed that CGA intervention reduced the incidence of dissection in the model mice.
[0033] like Figure 4 Shown are the echocardiograms of mice in each experimental group; Figure 5 The maximum diameter of the aorta of mice in each experimental group. The animal experiment was induced to 30 days, and the surviving mice were subjected to aortic ultrasound experiments. The intervention effect of CGA was evaluated by measuring the maximum diameter of the aorta and performing statistical analysis. The results showed that CGA intervention significantly reduced the aortic diameter expansion of the model mice.
[0034] By intragastric administration of CGA to mice with aortic dissection model, the incidence and mortality of dissection in mice were significantly reduced, and ultrasound results showed that CGA intervention alleviated the expansion of the aortic diameter of the model mice. The above pathological indicators show that CGA intervention effectively alleviates the occurrence and development of aortic dissection in mice.
[0035] This patent is currently limited to the intervention effect of CGA on mice with aortic dissection at the animal level, but whether it is applicable to clinical practice still requires further experimental verification.
[0036] The contents not described in detail in this specification belong to the prior art known to professional and technical personnel in this field.
[0037] Finally, it should be noted that the above description is only a preferred example of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art can still modify the technical solutions described in the aforementioned embodiments or replace some of the technical features therein by equivalents. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. The use of chlorogenic acid in preventing aortic dissection, characterized in that: Chlorogenic acid is used to intervene in aortic dissection and reduce the incidence of aortic dissection.
2. The use of chlorogenic acid in preventing aortic dissection according to claim 1, characterized in that: The application is use in preparing medicine or food for intervening aortic dissection.
3. The use of chlorogenic acid in preventing aortic dissection according to claim 1, characterized in that: The dosage of chlorogenic acid for intervention mice was 25 mg / kg / day.
4. A medicine or food comprising the chlorogenic acid according to claim 1, for use in preventing aortic dissection.
Citation Information
Cited By
Application of chlorogenic acid in preparation of medicine for preventing and treating aortic dissection
CN119055627A
Application of chlorogenic acid in preparation of medicine for preventing or treating aortic dissection
CN119112860A
Use of chlorogenic acid in preparation of drugs for preventing or treating aortic dissection
CN119112860B
Application of chlorogenic acid in preparation of medicine for preventing and treating aortic dissection
CN119606938A
Application of chlorogenic acid in the preparation of drugs for preventing and treating aortic dissection
CN119606938B
